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Supplementary Figure 1: A framework for stratification research using routine clinical and shared trial data 
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Supplementary Figure 2: Flow diagram showing the determination of the final CPRD datasets used in analysis, based on patients treated with thiazolidinediones (TZD) or 
sulfonylureas (SU).  Adherence measured by the medicine possession ratio. 
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Supplementary Table 1: CPRD population baseline characteristics split by cohorts treated with thiazolidinediones (TZD) and sulfonylureas (SU).  Data presented for the whole group 
and 4 subgroups defined by obesity (BMI>30kg/m2) and sex. 
 
All Non Obese Male Non Obese Female Obese Male Obese Female 
TZDs n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 10960 57.0 (9.9) 2825 57.6 (9.7) 1521 61.1 (9.9) 3030 54.7 (9.3) 2064 56.1 (9.7) 
Age (y) 10960 63.7 (10.4) 2825 65.3 (10.0) 1521 68.6 (10.1) 3030 60.6 (9.6) 2064 62.0 (10.0) 
Duration Diabetes* (y) 10960 5.4 (2.6, 10.9) 2825 6.2 (3.0, 12.8) 1521 6.0 (2.9, 12.4) 3030 4.8 (2.4, 9.4) 2064 4.7 (2.4, 9.4) 
BMI* (kg/m
2
) 9443 30.9 (25.8, 37.0) 2825 26.7 (24.4, 29.2) 1521 26.2 (23.6, 29.1) 3030 34.6 (30.9, 38.8) 2064 35.9 (31.3, 41.3) 
Male (%) 10960 62% 2825 100% 0 0% 3030 100% 0 0% 
Dose (weighted mean % max)** 10703 50 (50, 66.7) 2761 50 (50, 66.7) 1488 50 (49.8, 66.7) 2963 50 (50, 66.7) 2011 50 (50, 66.7) 
Adherence (%) 10960 101.1 (8.0) 2825 101.0 (8.0) 1521 101.4 (7.9) 3030 100.9 (8.1) 2064 101.2 (7.9) 
HbA1c (mmol/mol) 10960 71.0 (14.2) 2825 69.4 (13.0) 1521 70.7 (14.8) 3030 71.8 (14.4) 2064 71.6 (15.0) 
  All Non Obese Male Non Obese Female Obese Male Obese Female 
SUs n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 11419 59.3 (10.8) 2976 60.2 (10.4) 1603 64.5 (10.9) 2856 55.6 (9.6) 2103 57.8 (10.2) 
Age (y) 11419 64.6 (10.8) 2976 65.8 (10.3) 1603 69.7 (10.8) 2856 60.7 (9.9) 2103 62.9 (10.3) 
Duration Diabetes* (y) 11419 4.2 (2.1, 8.5) 2976 4.4 (2.1, 9.1) 1603 4.2 (2.1, 8.4) 2856 4.2 (2.2, 8.1) 2103 4.2 (2.1, 8.2) 
BMI* (kg/m
2
) 9539 30.6 (25.4, 36.8) 2976 26.5 (24.1, 29.1) 1603 26.0 (23.3, 29.1) 2856 34.6 (30.9, 38.8) 2103 36.0 (31.4, 41.2) 
Male (%) 11419 61% 2976 100% 0 0% 2856 100% 0 0% 
Dose (weighted mean % max)** 10958 25 (25, 44.5) 2853 25 (25, 37.8) 1541 25 (23.9, 33.2) 2745 25 (25, 50) 2011 25 (25, 47.7) 
Adherence (%) 11419 101.0 (8.6) 2976 100.7 (8.4) 1603 101.4 (8.5) 2856 100.8 (8.7) 2103 101.4 (8.7) 
HbA1c (mmol/mol) 11419 70.7 (16.0) 2976 69.4 (15.7) 1603 68.4 (15.0) 2856 71.9 (15.5) 2103 71.3 (16.1) 
*skewed data so presented as geometric mean (SD range).  **Dose presented as median (IQR) 
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Supplementary Figure 3: Coefficients for predictors of one year response with thiazolidinediones (TZDs) or sulfonylureas (SUs) in CPRD.  Data presented as beta coefficient from 





* TZD n=8291, SU n=8055 with valid baseline eGFR measure. TZD n=6184, SU n=5623 with valid baseline HDL measure. 
** Duration results presented but association was non-linear and showed poor model fit  
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Supplementary Figure 4a: CPRD one year response with a) Pioglitazone and b) Rosiglitazone (red dots), compared to sulfonylurea (blue triangles), by sex and obesity defined 
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Supplementary Figure 4b: CPRD one year response with a) Gliclazide and b) Non-gliclazide sulfonylureas (blue triangles), compared to thiazolidinediones (red dots), by sex and 
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Supplementary Table 2: Baseline characteristics for patients in the ADOPT trial, by sex and obesity defined subgroup and therapy.  Data presented as mean (SD) or *median (IQR) 
 
 Non-obese Male Obese Male Non-obese Female Obese Female 
 TZD SU TZD SU TZD SU TZD SU 
Patients (n) 373 395 402 387 208 174 407 379 
Age (years) 57.8 (10.0) 57.9 (9.9) 55.2 (9.5) 55.4 (9.3) 58.2 (10.1) 59.7 (10.4) 55.0 (9.9) 54.7 (10.6) 
Ethnic origin (white) 330 (88%) 362 (92%) 358 (89%) 347 (90%) 173 (83%) 161 (93%) 356 (87%) 326 (86%) 
Time since diagnosis 0.80 (0.89) 0.89 (0.91) 0.80 (0.88) 0.84 (0.89) 0.85 (0.85) 0.86 (1.23) 0.79 (0.83) 0.77 (0.82) 
Weight (kg) 81.9 (9.3) 82.6 (9.8) 106.7 (17.7) 108.1 (17.8) 68.7 (8.4) 69.2 (7.9) 97.2 (17.2) 97.1 (18.4) 
BMI 26.9 (2.1) 27.0 (2.0) 34.9 (4.7) 35.2 (4.6) 26.6 (2.5) 26.5 (2.5) 37.2 (6.0) 37.2 (5.9) 
Waist to hip ratio 0.97 (0.06) 0.96 (0.08) 1.00 (0.08) 1.00 (0.06) 0.89 (0.09) 0.89 (0.09) 0.90 (0.08) 0.90 (0.08) 
HbA1c (mmol/mol) 56.7 (11.0) 56.2 (11.2) 57.1 (10.1) 57.3 (9.5) 57.6 (10.3) 56.7 (10.3) 56.8 (9.1) 57.2 (9.3) 
Fasting glucose (mmol/l) 8.4 (1.6) 8.4 (1.4) 8.5 (1.5) 8.6 (1.6) 8.4 (1.3) 8.5 (1.8) 8.4 (1.3) 8.4 (1.4) 
Insulin sensitivity HOMA-S (%)* 46 (31-64) 45 (32-63) 28 (20-39) 28 (20-39) 43 (32-59) 41 (29-56) 27 (19-39) 26 (20-36) 
Beta-cell function HOMA-B (%)* 59 (46-79) 59 (47-73) 75 (59-95) 74 (57-94) 58 (46-73) 64 (46-81) 74 (58-91) 76 (59-94) 
Triglycerides (mmol/l)* 1.7 (1.2-2.4) 1.6 (1.1-2.4) 2.0 (1.4-3.0) 1.9 (1.4-2.7) 1.7 (1.2-2.3) 1.6 (1.2-2.3) 1.9 (1.4-2.6) 1.8 (1.4-2.4) 
LDL cholesterol (mmol/l)* 3.1 (2.5-3.7) 3.0 (2.5-3.6) 3.1 (2.5-3.6) 3.1 (2.5-3.7) 3.3 (2.6-3.9) 3.4 (2.7-4.0) 3.2 (2.7-3.8) 3.1 (2.6-3.8) 
HDL cholesterol (mmol/l)* 1.2 (1.0-1.4) 1.2 (1.0-1.4) 1.1 (0.9-1.3) 1.1 (0.9-1.3) 1.4 (1.2-1.6) 1.4 (1.2-1.6) 1.3 (1.1-1.5) 1.3 (1.1-1.5) 
 
  
{ PAGE   \* MERGEFORMAT } 
 
Supplementary Table 3: Baseline characteristics for patients in the RECORD trial, by sex and obesity defined subgroup and therapy.  Data presented as mean (SD) or *median (IQR) 
 
 
 Non-obese Male Obese Male Non-obese Female Obese Female 
 TZD SU TZD SU TZD SU TZD SU 
Patients (n) 240 228 361 356 137 127 379 394 
Age (years) 58.2 (8.4) 57.9 (8.5) 55.5 (7.8) 55.7 (8.0) 59.1 (7.7) 59.2 (8.2) 56.9 (7.8) 57.5 (7.8) 
Ethnic origin (white) 237 (99%) 223 (98%) 359 (99%) 351 (99%) 135 (99%) 122 (96%) 374 (99%) 391 (99%) 
Time since diagnosis 6.4 (4.4) 6.9 (4.4) 5.7 (3.7) 6.0 (4.4) 6.9 (4.9) 7.1 (4.7) 6.1 (4.2) 6.1 (4.3) 
Weight (kg) 85.7 (8.2) 86.2 (8.2) 106.6 (14.8) 106.0 (14.4) 72.9 (7.2) 73.1 (7.3) 93.4 (13.1) 92.4 (14.1) 
BMI 27.8 (1.5) 27.8 (1.5) 34.7 (3.9) 34.3 (4) 27.7 (1.5) 27.6 (1.7) 36.0 (4.4) 35.8 (4.9) 
Waist to hip ratio 0.97 (0.05) 0.98 (0.06) 1.01 (0.06) 1.01 (0.06) 0.90 (0.07) 0.91 (0.07) 0.92 (0.07) 0.92 (0.07) 
HbA1c (mmol/mol) 61.4 (7.3) 61.2 (7.2) 62.1 (7.5) 62.9 (7.7) 61.5 (7.3) 62.0 (6.8) 62.4 (7.3) 62.0 (6.7) 
Fasting glucose (mmol/l) 9.5 (2.0) 9.4 (2.0) 9.6 (2.3) 9.9 (2.2) 9.1 (2.0) 9.1 (1.9) 9.4 (1.9) 9.5 (2.2) 
Insulin sensitivity HOMA-S (%)* 87 (60-131) 93 (60-123) 52 (38-74) 52 (34-77) 80 (55-127) 79 (57-130) 58 (41-79) 58 (39-83) 
Beta-cell function HOMA-B (%)* 29 (21-39) 30 (20-42) 42 (30-60) 42 (25-58) 33 (23-42) 32 (22-47) 40 (30-54) 41 (28-57) 
Triglycerides (mmol/l)* 1.8 (1.3-2.5) 1.8 (1.2-2.7) 2.2 (1.7-3.0) 2.1 (1.4-3.1) 1.8 (1.3-2.7) 1.8 (1.3-2.3) 2.1 (1.6-2.7) 2.0 (1.5-2.8) 
LDL cholesterol (mmol/l)* 3.2 (2.6-3.6) 3.2 (2.6-3.7) 3.0 (2.5-3.6) 3.0 (2.4-3.6) 3.3 (2.8-3.9) 3.3 (2.8-3.9) 3.3 (2.7-3.9) 3.3 (2.6-3.9) 
HDL cholesterol (mmol/l)* 1.1 (1.0-1.3) 1.2 (1-1.3) 1.1 (0.9-1.2) 1.1 (0.9-1.2) 1.3 (1.1-1.5) 1.3 (1.1-1.5) 1.2 (1.1-1.4) 1.2 (1.1-1.4) 
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Supplementary Figure 5: ADOPT Kaplan–Meier estimates of the cumulative incidence of monotherapy failure with thiazolidinediones (red) and sulfonylureas (blue) over 5 years by 
sex and obesity defined subgroup.  Failure defined as confirmed fasting plasma glucose ≥ 180 mg/dl. 
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Supplementary Figure 6: RECORD Kaplan–Meier estimates of the cumulative incidence of dual therapy failure with thiazolidinediones (red) and sulfonylureas (blue) over 5 years 
by sex and obesity defined subgroup.  Failure defined as confirmed HbA1c ≥8.5% 
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Supplementary Figure 7: RECORD percentage weight change from baseline over 5 years with thiazolidinediones (red dots) and sulfonylureas (blue triangles), by sex and obesity 
defined subgroup. Data are presented as means at each study visit ± standard error from mixed effects models, adjusted for baseline weight. Number (n) per year presented below plots for 
each therapy and subgroup. 
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Supplementary Figure 8: ADOPT & RECORD combined Kaplan–Meier estimates of the cumulative incidence of moderate/severe oedema over 5 years with thiazolidinediones (red) 
and sulfonylureas (blue) 
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Supplementary Figure 9: ADOPT & RECORD combined Kaplan–Meier estimates of the cumulative incidence of fracture (any) over 5 years with thiazolidinediones (red) and 
sulfonylureas (blue). 
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Supplementary Figure 10: ADOPT & RECORD combined Kaplan–Meier estimates of the cumulative incidence of moderate/severe hypoglycaemia over 5 years with 
thiazolidinediones (red) and sulfonylureas (blue) 
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Supplementary Table 4: ADOPT absolute and relative risk of side effects over 5 years with thiazolidinediones (TZD) and sulfonylureas (SU), by sex and obesity defined subgroup.  











 TZD SU TZD SU TZD SU   
Non-obese males 
Oedema 367 392 16 12 6% 5% 1.44 (0.68-3.03) 0.34 
Oedema 
(Moderate/Severe) 
367 392 6 3 2% 2% 2.16 (0.54-8.63) 0.28 
Fracture 373 395 12 12 4% 5% 1.06 (0.48-2.37) 0.88 
Hypoglycaemia 
(All) 
373 395 33 161 10% 49% 0.18 (0.12-0.25) <0.01 
Hypoglycaemia 
(Moderate/Severe) 
373 395 12 74 4% 22% 0.16 (0.09-0.29) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
Obese males 
Oedema 379 363 52 34 19% 13% 1.33 (0.86-2.05) 0.20 
Oedema 
(Moderate/Severe) 
379 363 13 10 5% 4% 1.10 (0.48-2.51) 0.83 
Fracture 402 387 18 14 6% 5% 1.09 (0.54-2.20) 0.81 
Hypoglycaemia 
(All) 
402 387 36 120 11% 40% 0.23 (0.16-0.33) <0.01 
Hypoglycaemia 
(Moderate/Severe) 
402 387 8 52 2% 16% 0.13 (0.06-0.28) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
Non-obese females 
Oedema 203 166 31 12 19% 9% 2.07 (1.06-4.03) 0.03 
Oedema 
(Moderate/Severe) 
203 166 10 4 6% 3% 1.94 (0.61-6.19) 0.26 
Fracture 208 174 19 4 18% 3% 3.42 (1.16-10.07) 0.03 
Hypoglycaemia 
(All) 
208 174 20 64 13% 52% 0.20 (0.12-0.33) <0.01 
Hypoglycaemia 
(Moderate/Severe) 
208 174 6 34 3% 26% 0.13 (0.05-0.31) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
Obese females 
Oedema 370 352 78 46 29% 20% 1.36 (0.94-1.96) 0.10 
Oedema 
(Moderate/Severe) 
370 352 32 19 12% 11% 1.30 (0.74-2.31) 0.36 
Fracture 407 379 41 14 16% 9% 2.17 (1.18-3.98) 0.01 
Hypoglycaemia 
(All) 
407 379 50 137 15% 45% 0.26 (0.19-0.36) <0.01 
Hypoglycaemia 
(Moderate/Severe) 
407 379 14 59 5% 19% 0.19 (0.10-0.33) <0.01 
Hypoglycaemia 
(Severe) 
  24 events total across all 4 subgroups with both therapies - 21 SU, 3 TZD  
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Supplementary Table 5: RECORD absolute and relative risk of side effects over 5 years with thiazolidinediones (TZD) and sulfonylureas (SU), by sex and obesity defined subgroup.  












 TZD SU TZD SU TZD SU   
Non-obese males 
Oedema 240 228 13 9 7% 5% 1.59 (0.68-3.71) 0.29 
Oedema 
(Moderate/Severe) 
240 228 7 1 4% 1% 7.84 (0.96-63.7) 0.05 
Fracture 240 228 14 6 9% 3% 2.66 (1.02-6.94) 0.04 
Hypoglycaemia 
(All) 
240 228 5 38 2% 18% 0.12 (0.05-0.31) <0.01 
Hypoglycaemia 
(Moderate/Severe) 
240 228 2 16 1% 8% 0.12 (0.03-0.54) <0.01 
Hypoglycaemia 
(Severe) 
  10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD  
Obese males 
Oedema 361 356 48 21 17% 7% 2.61 (1.56-4.35) <0.01 
Oedema 
(Moderate/Severe) 361 356 
24 6 9% 2% 4.45 (1.82-10.90) <0.01 
Fracture 361 356 12 14 5% 5% 0.94 (0.43-2.03) 0.88 
Hypoglycaemia 
(All) 361 356 10 51 3% 16% 0.19 (0.10-0.38) <0.01 
Hypoglycaemia 
(Moderate/Severe) 361 356 5 18 2% 6% 0.29 (0.11-0.79) 0.015 
Hypoglycaemia 
(Severe)   
10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD 
 
Non-obese females 
Oedema 137 127 17 4 15% 4% 4.13 (1.39-12.2) 0.01 
Oedema 
(Moderate/Severe) 137 127 
3 1 3% 1% 2.77 (0.29-26.60) 0.38 
Fracture 137 127 12 4 11% 3% 2.86 (0.92-8.88) 0.07 
Hypoglycaemia 
(All) 137 127 3 26 3% 22% 0.10 (0.03-0.31) <0.01 
Hypoglycaemia 
(Moderate/Severe) 137 127 4 10 4% 9% 0.36 (0.11-1.3) 0.08 
Hypoglycaemia 
(Severe)   
10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD 
 
Obese females 
Oedema 379 394 75 20 23% 6% 4.37 (2.67-7.16) <0.01 
Oedema 
(Moderate/Severe) 379 394 
28 6 9% 2% 5.16 (2.14-12.46) <0.01 
Fracture 379 394 36 19 12% 5% 2.12 (1.21-3.70) <0.01 
Hypoglycaemia 
(All) 379 394 14 73 4% 21% 0.19 (0.11-0.34) <0.01 
Hypoglycaemia 
(Moderate/Severe) 379 394 4 24 1% 7% 0.17 (0.06-0.50) <0.01 
Hypoglycaemia 
(Severe)   
10 events total across all 4 subgroups with both therapies - 10 SU, 0 TZD 
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Supplementary Figure 11: CPRD HbA1c over 5 years with thiazolidinediones (red dots) and sulfonylureas (blue triangles), by sex and obesity defined subgroup. Data are presented as 
3 monthly means ± standard error from mixed effects models, adjusted for baseline HbA1c. Number (n) per year presented below plots for each therapy and subgroup. 
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Supplementary Figure 12: CPRD Kaplan–Meier estimates of the cumulative incidence of failure of therapy over 5 years with thiazolidinediones (red) and sulfonylureas (blue) 
Failure defined as two consecutive HbA1cs >8.5% or one HbA1c >8.5% followed by an additional oral hypoglycaemic agent being added. 
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Supplementary Figure 13: CPRD percentage weight change from baseline over 5 years with thiazolidinediones (red dots) and sulfonylureas (blue triangles), by sex and obesity 
defined subgroup. Data are presented as 6 monthly means ± standard error from mixed effects models, adjusted for baseline HbA1c.  Number (n) per year presented below plots for each 
therapy and subgroup. 
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Supplementary Figure 14: CPRD Kaplan–Meier estimates of the cumulative incidence of oedema over 5 years with thiazolidinediones (red) and sulfonylureas (blue) 
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Supplementary Figure 15: CPRD Kaplan–Meier estimates of the cumulative incidence of fracture (any) over 5 years with thiazolidinediones (red) and sulfonylureas (blue) 
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Supplementary Table 6: GoDARTs population baseline characteristics, split by cohorts treated with thiazolidinediones (TZD) and sulfonylureas (SU).  Data presented for the whole 
group and 4 subgroups defined by obesity (BMI>30kg/m2) and sex. 
 
All Non Obese Male Non Obese Female Obese Male Obese Female 
TZD n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 719 55.6 (9.3) 176 56.7 (9.2) 97 59.9 (8.5) 267 52.9 (9.0) 174 56.1 (9.1) 
Age (y) 719 63.7 (9.6) 176 65.9 (9.0) 97 69.0 (8.8) 267 60.7 (9.3) 174 63.3 (9.3) 
Duration Diabetes (y) 719 8.2 (5.1) 176 9.2 (5.9) 97 9.2 (5.2) 267 7.8 (4.9) 174 7.2 (4.0) 
BMI (kg/m
2
) 714 32.2 (5.7) 176 27.3 (2.0) 97 26.8 (2.5) 267 34.9 (4.6) 174  36.0 (5.6) 
Male (%) 719 62 176 100 97 0 267 100 174 0 
Dose (weighted mean % max) 686 50 (23) 170 51 (25) 95 49 (22) 252 51 (23) 164 48 (22) 
Adherence (%) 719 97 (5) 176 97 (5) 97 98 (3) 267 97 (5) 174 97 (5) 
HbA1c (mmol/mol) 719 73.1 (12.5) 176 70.8 (12.0) 97 71.0 (11.6) 267 74.3 (12.5) 174 74.6 (13.0) 
  All Non Obese Male Non Obese Female Obese Male Obese Female 
SU n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) n Mean(SD) 
Age diag (y) 1258 58.8 (10.4) 350 59.8 (10.0) 219 64.0 (10.5) 336 56.1 (9.6) 285 57.2 (10.3) 
Age (y) 1258 64.6 (10.2) 350 66.0 (9.9) 219 69.3 (9.8) 336 61.9 (9.6) 285 62.9 (10.3) 
Duration Diabetes (y) 1258 5.8 (3.9) 350 6.2 (4.4) 219 5.4 (3.5) 336 5.8 (3.7) 285 5.7 (3.7) 
BMI (kg/m
2
) 1190 31.2 (5.5) 350 27.1 (2.1) 219 26.4 (2.5) 336 34.6 (4.1) 285 35.8 (4.8) 
Male (%) 1258 57 350 100 219 0 336 100 285 0 
Dose (weighted mean % max) 1167 29 (22) 330 26 (14) 202 24 (14) 307 30 (15) 268 37 (31) 
Adherence (%) 1258 96 (6) 350 96 (6) 219 96 (6) 336 96 (5) 285 97 (5) 
HbA1c (mmol/mol) 1258 70.9 (14.5) 350 68.8 (14.3) 219 69.0 (12.8) 336 71.4 (13.8) 285 72.9 (14.9) 
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Supplementary Figure 16: GoDARTs  HbA1c over 5 years with thiazolidinediones (red dots) and sulfonylureas (blue triangles), by sex and obesity defined subgroup. Data are 



































































































306 262 188 126 95 53
362 362 270 191 136 95
445 406 314 218 143 95
557 522 395 290 205 144
TZD (n)
SU (n)
179 156 115 92 65 38
200 201 149 109 81 61
332 300 225 174 122 70
480 440 328 241 168 117
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CPRD – data supplement 
Therapy records 
Medcodes for prescriptions of sulfonylureas and thiazolidinediones were identified using BNF codes and 
keyword searches of “product name” and “drug substance name”.  Records matching the following medcodes in 
the Therapy file were extracted: 
Prod-
code productname drugsubstancename 
Thiazolidinediones 
469 Rosiglitazone 4mg tablets Rosiglitazone maleate 
548 Pioglitazone 15mg tablets Pioglitazone hydrochloride 
5227 Rosiglitazone 8mg tablets Rosiglitazone maleate 
9662 Avandia 4mg tablets (GlaxoSmithKline UK Ltd) Rosiglitazone maleate 
9699 Pioglitazone 30mg tablets Pioglitazone hydrochloride 
10051 Pioglitazone 45mg tablets Pioglitazone hydrochloride 
13628 Romozin 400mg Tablet (Glaxo Wellcome UK Ltd) Troglitazone 
15232 Avandia 8mg tablets (GlaxoSmithKline UK Ltd) Rosiglitazone maleate 
19472 Actos 45mg tablets (Takeda UK Ltd) Pioglitazone hydrochloride 
20287 Actos 15mg tablets (Takeda UK Ltd) Pioglitazone hydrochloride 
20889 Actos 30mg tablets (Takeda UK Ltd) Pioglitazone hydrochloride 
37617 Rosiglitazone 2mg tablet Rosiglitazone Maleate 
48120 Avandia 2mg Tablet (GlaxoSmithKline UK Ltd) Rosiglitazone Maleate 
48139 Pioglitazone 30mg tablets (A A H Pharmaceuticals Ltd) Pioglitazone hydrochloride 
56208 Pioglitazone 15mg tablets (A A H Pharmaceuticals Ltd) Pioglitazone hydrochloride 
56376 Rosiglitazone 4mg with glimepiride 4mg tablet Rosiglitazone Maleate 
56831 Troglitazone 200mg Tablet  
Sulfonylureas 
32 Gliclazide 80mg tablets Gliclazide 
547 Glipizide 2.5mg tablets Glipizide 
1253 Chlorpropamide 100mg tablets Chlorpropamide 
1254 Glibenclamide 5mg tablets Glibenclamide 
1847 Chlorpropamide 250mg tablets Chlorpropamide 
1964 Diamicron 80mg tablets (Servier Laboratories Ltd) Gliclazide 
1965 Tolbutamide 500mg tablets Tolbutamide 
2219 Glibenclamide 2.5mg tablets Glibenclamide 
4862 Diabetamide 2.5mg tablets (Ashbourne Pharmaceuticals Ltd) Glibenclamide 
5276 Glimepiride 1mg tablets Glimepiride 
5316 Glimepiride 4mg tablets Glimepiride 
5353 Glimepiride 2mg tablets Glimepiride 
5627 Gliclazide 30mg modified-release tablets Gliclazide 
5636 Glipizide 5mg tablets Glipizide 
6337 Glimepiride 3mg tablets Glimepiride 
7284 Amaryl 2mg tablets (Zentiva) Glimepiride 
7332 Amaryl 1mg tablets (Zentiva) Glimepiride 
7409 Amaryl 3mg tablets (Zentiva) Glimepiride 
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7744 Daonil 5mg tablets (Sanofi) Glibenclamide 
7912 Semi-Daonil 2.5mg tablets (Sanofi) Glibenclamide 
8034 Diabinese 100mg Tablet (Pfizer Ltd) Chlorpropamide 
8168 Diabinese 250mg Tablet (Pfizer Ltd) Chlorpropamide 
8976 Euglucon 2.5mg tablets (Aventis Pharma) Glibenclamide 
9108 TOLBUTAMIDE 250 MG TAB  
10427 Tolazamide 250mg Tablet Tolazamide 
11284 Amaryl 4mg tablets (Zentiva) Glimepiride 
11695 Diamicron 30mg MR tablets (Servier Laboratories Ltd) Gliclazide 
11946 Tolbutamide 50mg/ml Injection Tolbutamide 
12245 Glutril 25mg Tablet (Roche Products Ltd) Glibornuride 
12259 Glibornuride 25mg Tablet Glibornuride 
12455 Rastinon 500mg Tablet (Hoechst Marion Roussel) Tolbutamide 
12513 Glibenese 5mg tablets (Pfizer Ltd) Glipizide 
13331 Euglucon 5mg tablets (Sanofi) Glibenclamide 
15374 Gliclazide 40mg/5ml oral suspension Gliclazide 
16211 TOLBUTAMIDE 100 MG TAB  
16602 Calabren 2.5mg Tablet (Berk Pharmaceuticals Ltd) Glibenclamide 
17343 Gliclazide 80mg tablets (A A H Pharmaceuticals Ltd) Gliclazide 
17698 Minodiab 5mg tablets (Pfizer Ltd) Glipizide 
17706 Minodiab 2.5mg tablets (Pfizer Ltd) Glipizide 
19336 Tolazamide 100mg Tablet Tolazamide 
21424 Glibenclamide 5mg/5ml oral suspension Glibenclamide 
21489 Tolanase 250mg Tablet (Pharmacia Ltd) Tolazamide 
21564 Gliclazide 80mg tablets (Wockhardt UK Ltd) Gliclazide 
21832 Diabetamide 5mg tablets (Ashbourne Pharmaceuticals Ltd) Glibenclamide 
21892 Diaglyk 80mg tablets (Ashbourne Pharmaceuticals Ltd) Gliclazide 
22145 Tolanase 100mg Tablet (Pharmacia Ltd) Tolazamide 
22614 DAONIL 10 MG TAB  
22636 TOLBUTAMIDE 1 GM TAB  
22858 Acetohexamide 500mg tablets Acetohexamide 
24848 Glymidine sodium 500mg Tablet Glymidine Sodium 
25636 Libanil 2.5mg Tablet (Approved Prescription Services Ltd) Glibenclamide 
26118 Dimelor 500mg Tablet (Eli Lilly and Company Ltd) Acetohexamide 
26218 Calabren 5mg Tablet (Berk Pharmaceuticals Ltd) Glibenclamide 
27969 Glymese 250mg Tablet (DDSA Pharmaceuticals Ltd) Chlorpropamide 
28708 Malix 2.5mg Tablet (Lagap) Glibenclamide 
29326 Glipizide 5mg tablets (Generics (UK) Ltd) Glipizide 
29939 Gliclazide 80mg tablets (Generics (UK) Ltd) Gliclazide 
30460 Malix 5mg Tablet (Lagap) Glibenclamide 
31212 Gliclazide 80mg tablets (Actavis UK Ltd) Gliclazide 
31474 Libanil 5mg Tablet (Approved Prescription Services Ltd) Glibenclamide 
33562 Duclazide 80mg Tablet (Dumex Ltd) Gliclazide 
33673 Tolbutamide 500mg tablets (Actavis UK Ltd) Tolbutamide 
34399 Gliclazide 80mg tablets (IVAX Pharmaceuticals UK Ltd) Gliclazide 
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34507 Glibenclamide 2.5mg tablets (Wockhardt UK Ltd) Glibenclamide 
34563 Glibenclamide 5mg tablets (Wockhardt UK Ltd) Glibenclamide 
34676 Glibenclamide 2.5mg tablets (A A H Pharmaceuticals Ltd) Glibenclamide 
34706 Glibenclamide 2.5mg tablets (IVAX Pharmaceuticals UK Ltd) Glibenclamide 
34802 Glipizide 5mg tablets (IVAX Pharmaceuticals UK Ltd) Glipizide 
34932 Gliclazide 80mg tablets (Genus Pharmaceuticals Ltd) Gliclazide 
34957 Tolbutamide 500mg tablets (A A H Pharmaceuticals Ltd) Tolbutamide 
36856 Gliclazide 80mg tablets (Sandoz Ltd) Gliclazide 
40365 Glimepiride 1mg tablets (Actavis UK Ltd) Glimepiride 
40425 Nazdol MR 30mg tablets (Teva UK Ltd) Gliclazide 
41558 Glibenclamide 5mg tablets (Teva UK Ltd) Glibenclamide 
41559 Glibenclamide 5mg tablets (A A H Pharmaceuticals Ltd) Glibenclamide 
41593 Glibenclamide 2.5mg tablets (Teva UK Ltd) Glibenclamide 
42790 Gliclazide 80mg Tablet (Merck Generics (UK) Ltd) Gliclazide 
43065 Gliclazide 40mg tablets Gliclazide 
43465 Zicron 40mg tablets (Bristol Laboratories Ltd) Gliclazide 
44304 Glyconon 500mg Tablet (DDSA Pharmaceuticals Ltd) Tolbutamide 
44473 Edicil MR 30mg tablets (Ratiopharm UK Ltd) Gliclazide 
44738 Niddaryl 1mg tablets (Dee Pharmaceuticals Ltd) Glimepiride 
45215 Gliclazide 80mg Tablet (Neo Laboratories Ltd) Gliclazide 
45831 Dacadis MR 30mg tablets (Generics (UK) Ltd) Gliclazide 
46927 Tolbutamide 500mg tablets (Teva UK Ltd) Tolbutamide 
47074 Gliclazide 80mg/5ml oral suspension Gliclazide 
47894 Nazdol MR 30mg tablets (Consilient Health Ltd) Gliclazide 
48056 Gliclazide 80mg tablets (Sovereign Medical Ltd) Gliclazide 
51955 Gliclazide 80mg tablets (Accord Healthcare Ltd) Gliclazide 
53288 Gliclazide 30mg modified-release tablets (A A H Pharmaceuticals Ltd) Gliclazide 
54764 Gliclazide 80mg tablets (Arrow Generics Ltd) Gliclazide 
55862 Gliclazide Oral solution Gliclazide 
56008 Gliclazide 80mg tablets (Almus Pharmaceuticals Ltd) Gliclazide 
56437 Gliclazide 60mg modified-release tablets Gliclazide 
 
For combined metformin and thiazolidinedione medications, the doses of each medication were extracted 
separately.  Where there were two prescriptions for the same medication on the same date, the mean of the non-
zero quantities was taken. 
HbA1cs  


























Oedema was identified using clinical codes relating to keywords associated with oedema, swelling etc.  Two 
researchers independently searched the medical code database and compared results.  The full list of codes is 
below: 
medcode readcode description 
387 N247013 Swollen legs 
1284 22C3.00 O/E - oedema of feet 
1906 22C2.11 O/E - ankle oedema 
2140 183..12 Swelling - oedema - symptom 
3158 183..00 Oedema 
4950 R023.00 [D]Oedema 
5889 1832.11 Ankle swelling symptom 
5919 1833.11 Leg swelling symptom 
6047 183..11 Oedema - symptom 
6585 22C4.11 O/E - leg oedema 
6651 22C..11 O/E - swelling - oedema 
6764 22C8.11 O/E - scrotal oedema 
7106 22C3.11 O/E - foot oedema 
7122 1832 Ankle swelling 
9108 1837 Pitting oedema 
9392 22C7.00 O/E - sacral oedema 
10931 22C..00 O/E - oedema 
14702 R023z00 [D]Oedema NOS 
15047 1833 Leg swelling 
15477 R023z11 [D]Dependent oedema 
19358 22C4.00 O/E - oedema of legs 
19714 22C5.11 O/E - thigh oedema 
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20301 R023000 [D]Oedema, generalized 
20553 22C2.00 O/E - oedema of ankles 
22500 8E95.00 Reduction of oedema 
22734 1838 Sacral oedema 
28107 L161.00 Oedema or excessive weight gain in pregnancy no hypertension 
28419 22CZ.00 O/E - oedema NOS 
29565 L161.13 Gestational oedema 
30309 183Z.00 Oedema NOS 
36394 L16C.00 Pregnancy induced oedema+proteinuria without hypertension 
37201 L16C100 Gestational oedema with proteinuria 
43618 G581.12 Pulmonary oedema - acute 
49411 22C8.00 O/E - genital oedema 
53921 L161000 Oedema or excessive weight gain in pregnancy, unspecified 
61224 22C5.00 O/E - oedema of thighs 
61563 L161300 Oedema or excessive weight gain in pregnancy - not delivered 
61835 L161z00 Oedema or excessive weight gain in pregnancy NOS 
92998 Lyu1.00 [X]Oedema,proteinuria+hypertens in pregnancy,childbrth,puerp 
98612 1839 Oedema of calf 
103579 183C.00 Reduction in peripheral oedema 
558 H584.00 Acute pulmonary oedema unspecified 
5155 23E1.00 O/E - pulmonary oedema 
5293 H584z00 Acute pulmonary oedema NOS 
7321 H541z00 Pulmonary oedema NOS 
24552 SN27.00 Heat oedema 
26082 H541000 Chronic pulmonary oedema 
39706 H584000 Postoperative pulmonary oedema 
48466 H584.11 Acute oedema of lung, unspecified 
102627 183B.00 Worsening pulmonary oedema 
102720 183A.00 Worsening peripheral oedema 
 
Fracture 
Fracture codes were identified from read codes associated with fracture, as identified as part of another study of 
fragility fractures (Erwin J. Research Associate. Personal communication. 8th Dec 2015. List based on: Staa 
TPV, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C: Clinical assessment of the long-term risk of fracture 
in patients with rheumatoid arthritis. Arthritis & Rheumatism 2006;54:3104-3112). The full list of read codes is 
below: 
medcode readcode description 
11503 N331M00 Fragility fracture due to unspecified osteoporosis 
93497 N331N00 Fragility fracture 
23803 S301800 Open fracture proximal femur,subcapital, Garden grade III 
29145 S302200 Closed fracture proximal femur, subtrochanteric 
33957 S300700 Closed fracture proximal femur, subcapital, Garden grade II 
34078 S300900 Closed fracture proximal femur, subcapital, Garden grade IV 
34351 S300600 Closed fracture proximal femur, subcapital, Garden grade I 
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36599 S300800 Closed fracture proximal femur, subcapital, Garden grade III 
38489 S300.00 Closed fracture proximal femur, transcervical 
38878 S301500 Open fracture proximal femur,subcapital, Garden grade unspec 
45141 S302100 Closed fracture proximal femur, intertrochanteric, two part 
49209 S300y00 Closed fracture proximal femur, other transcervical 
51999 S301900 Open fracture proximal femur,subcapital, Garden grade IV 
52194 S300300 Closed fracture proximal femur, basicervical 
137 S23x111 Fracture of radius NOS 
199 S23B.00 Fracture of lower end of radius 
203 S234.11 Wrist fracture - closed 
280 S120.00 Closed fracture rib 
343 S234100 Closed Colles' fracture 
358 S3z..11 Fracture NOS 
455 S3z0000 Greenstick fracture 
517 S22..00 Fracture of humerus 
520 S31z.00 Fracture of femur, NOS 
553 S242000 Fracture of scaphoid 
738 S13..00 Fracture or disruption of pelvis 
835 S10B200 Fracture of coccyx 
868 S4...13 Fracture dislocations and fracture subluxations 
909 S23z.00 Fracture of radius and ulna, NOS 
1073 S23x211 Fracture of ulna NOS 
1177 S21..00 Fracture of scapula 
1250 S224.11 Elbow fracture - closed 
1548 S228.00 Fracture of lower end of humerus 
1591 S130.00 Closed fracture acetabulum 
1700 S352.11 March fracture 
1742 S234200 Closed fracture of the distal radius, unspecified 
1857 S354.00 Fracture of calcaneus 
1994 S30..11 Hip fracture 
2101 S226.00 Fracture of upper end of humerus 
2225 S30..00 Fracture of neck of femur 
2303 S237.00 Fracture of upper end of radius 
2328 S10B500 Fracture of pubis 
2442 S355.00 Fracture of talus 
2461 S01..00 Fracture of base of skull 
2603 S3...11 Leg fracture 
2662 S230300 Closed Monteggia's fracture 
3025 S3z2.00 Stress fracture 
3288 S10A.00 Fracture of neck 
3573 S10x.00 Closed fracture of spine, unspecified, 
3675 S10B100 Fracture of sacrum 
3748 S233.00 Open fracture of radius and ulna, shaft 
3888 S104.00 Closed fracture lumbar vertebra 
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3983 S122.00 Closed fracture sternum 
4013 N331L00 Collapse of vertebra due to osteoporosis NOS 
4359 S23x300 Closed fracture of the radius and ulna 
4409 S10..12 Fracture of vertebra without spinal cord lesion 
5301 S302.00 Closed fracture of proximal femur, pertrochanteric 
5332 S312300 Closed fracture distal femur, supracondylar 
5381 S15..00 Fracture of thoracic vertebra 
5841 N331J00 Collapse of lumbar vertebra due to osteoporosis 
6213 S23C.00 Fracture of lower end of both ulna and radius 
6320 S312100 Closed fracture of femoral condyle, unspecified 
6667 S132100 Closed fracture pelvis, multiple pubic rami - stable 
6825 S23..00 Fracture of radius and ulna 
6868 S310.00 Closed fracture of femur, shaft or unspecified part 
6893 S224100 Closed fracture distal humerus, supracondylar 
7004 S132000 Closed fracture pelvis, single pubic ramus 
7009 S230600 Closed fracture radius, head 
7636 S231600 Open fracture radial head 
7660 S230700 Closed fracture radius, neck 
7988 S239.00 Fracture of shaft of radius 
8040 S31..00 Other fracture of femur 
8056 S242.00 Fracture at wrist and hand level 
8243 S305.00 Subtrochanteric fracture 
8255 S10..00 Fracture of spine without mention of spinal cord injury 
8266 S104100 Closed fracture lumbar vertebra, wedge 
8382 S238.00 Fracture of shaft of ulna 
8410 S231B00 Open fracture olecranon, intra-articular 
8589 S315.00 Fracture of lower end of femur 
8613 S10B600 Multiple fractures of lumbar spine and pelvis 
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